OpenLegislation

Division 1 Identification of the productF1

United Kingdom

Original text. Later amendments are not shown.

An identification of the veterinary medicinal product(s) used in the testing shall be provided, including:

  • composition,

  • the physical and chemical (potency and purity) test results for the relevant batch(es),

  • batch identification,

  • relationship to the final product,

  • specific activity and radio-purity of labelled substances,

  • position of labelled atoms in the molecule.

The dossier of residue tests shall include:

  • an index of all studies included in the dossier,

  • a statement confirming that all data known by the applicant at the time of submission, whether favourable or unfavourable, are included,

  • a justification for the omission of any type of study,

  • an explanation of the inclusion of an alternative type of study,

  • a discussion of the contribution that any study that pre-dates GLP can make to the overall risk assessment,

  • a withdrawal period proposal.

Each study report shall include:

  • a copy of the study plan (protocol),

  • a statement of compliance with good laboratory practice, where applicable,

  • a description of the methods, apparatus and materials used,

  • a description of the results obtained, in sufficient detail to allow the results to be critically evaluated independently of their interpretation by the author,

  • a statistical analysis of the results where appropriate,

  • a discussion of the results,

  • an objective discussion of the results obtained, and proposals concerning the withdrawal periods necessary to ensure that no residues which might constitute a hazard for consumers are present in foodstuffs obtained from treated animals.

Annotations

Textual amendments

F1

Substituted by Commission Directive 2009/9/EC of 10 February 2009 amending Directive 2001/82/EC of the European Parliament and of the Council on the Community code relating to medicinal products for veterinary use (Text with EEA relevance).